BridgeBio has substantially improved the progress of a novel therapy for amyloid heart disease, leveraging the investigational drug. Initial trial data reveals potential outcomes for patients suffering from a serious https://biotech741143.blog2news.com/42643695/company-improves-cardiac-amyloidosis-therapy-with-the-therapy